Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by GenSight Biologics

GenSight Biologics Annual General Meeting on May 13, 2025
From GenSight Biologics
Via Business Wire
GenSight Biologics Reports Cash Position as of March 31, 2025, and Provides Business Update
From GenSight Biologics
Via Business Wire
GenSight Biologics Confirms Definitive Full-Year 2024 Consolidated Financial Results Are in Line with Estimates
From GenSight Biologics
Via Business Wire
GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2025
From GenSight Biologics
Via Business Wire
GenSight Biologics Announces Five-Year Efficacy and Safety Results for LUMEVOQ® Gene Therapy at the Conclusion of the REFLECT Study
From GenSight Biologics
Via Business Wire
GenSight Biologics Reports End-of-Year Cash Position and Provides Business Update
From GenSight Biologics
Via Business Wire
GenSight Biologics Announces LUMEVOQ® Scientific Updates at AAO 2024
From GenSight Biologics
Via Business Wire
GenSight Biologics Launches Newsletter for Retail Investors
From GenSight Biologics
Via Business Wire
GenSight Biologics to Present at Upcoming Medical Conferences and Stakeholder Meetings
From GenSight Biologics
Via Business Wire
GenSight Biologics Appoints William Monteith to its Board of Directors
From GenSight Biologics
Via Business Wire
GenSight Biologics: Annual General Meeting on May 29, 2024
From GenSight Biologics
Via Business Wire
GenSight Biologics Announces the Filing of its 2023 Universal Registration Document
From GenSight Biologics
Via Business Wire
GenSight Biologics Announces its 2024 Financial Calendar
From GenSight Biologics
Via Business Wire
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections Four Years After One-Time Administration
From GenSight Biologics
Via Business Wire
GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2024
From GenSight Biologics
Via Business Wire
GenSight Biologics Announces 1 Year Safety Data and Efficacy Signals from PIONEER Phase I/II Clinical Trial of GS030, an Optogenetic Treatment Candidate for Retinitis Pigmentosa
From GenSight Biologics
Via Business Wire
GenSight Biologics Announces Publication of Indirect Comparison of LUMEVOQ® Versus Natural History in ND4-LHON Patients in Peer-Reviewed Journal Ophthalmology and Therapy
From GenSight Biologics
Via Business Wire
GenSight Biologics reports 5 years’ data showing sustained efficacy and safety following one-time treatment with LUMEVOQ®
From GenSight Biologics
Via Business Wire
GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection
From GenSight Biologics
Via Business Wire
GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US
From GenSight Biologics
Via Business Wire
GenSight Biologics Reports Second Patient Case Showing Significant Visual Recovery after GS030 Optogenetic Treatment
From GenSight Biologics
Via Business Wire
GenSight Biologics to Present New Clinical Data of LUMEVOQ® and GS030 Gene Therapies at the American Academy of Ophthalmology 2021 Meeting
From GenSight Biologics
Via Business Wire
GenSight Biologics Announces FDA Grant of Fast Track Designation for Optogenetic Therapy GS030 as Treatment for Retinitis Pigmentosa
From GenSight Biologics
Via Business Wire
GenSight Biologics Announces Positive Data Safety Monitoring Board Review of PIONEER Phase I/II Clinical Trial of GS030 as Optogenetic Treatment for Retinitis Pigmentosa
From GenSight Biologics
Via Business Wire
UK MHRA Grants GenSight Biologics’ LUMEVOQ® Ophthalmic Gene Therapy Promising Innovative Medicine Designation
From GenSight Biologics
Via Business Wire
GenSight Biologics Announces Publication of RESTORE Study Data Demonstrating Sustained Efficacy 3 Years After Unilateral Injection of LUMEVOQ®
From GenSight Biologics
Via Business Wire
GenSight Biologics Announces Approval of the LUMEVOQ® Cohort Temporary Authorization for Use (ATUc) in France
From GenSight Biologics
Via Business Wire
GenSight Biologics Reports Topline Results from REFLECT Phase III Clinical Trial, Confirming LUMEVOQ® Efficacy Including Better Efficacy with Bilateral Treatment
From GenSight Biologics
Via Business Wire
GenSight Biologics Appoints Marion Ghibaudo as Chief Technical Officer to Lead GS030 Device Engineering
From GenSight Biologics
Via Business Wire
GenSight Biologics Announces Publication of Indirect Comparison Showing Treatment Effect of LUMEVOQ® versus Natural History in Frontiers in Neurology
From GenSight Biologics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.